IDH1 and central nervous system cancer: Some existing molecular biomarkers, such as GFAP, IDH1 and Ki-67 antigen [28–31], are helpful for the diagnosis of molecular subtypes, individualized treatment and clinical prognosis of glioma, but their sensitivity and accuracy are still lacking.